Physician profile
Duc Phan
NPI 1083946693
$25,039.70
in general payments reported to CMS, 2019-2025
60 companies · $3,193 in 2025
The $3,193 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,197 · 2020: $3,136 · 2021: $4,249 · 2022: $4,211 · 2023: $3,931 · 2024: $3,124 · 2025: $3,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $60.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,187.15 |
| Education | $60.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,438.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,523.89 | 2019-2025 | |
| Novo Nordisk INC | $1,793.47 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,607.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,588.17 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,567.35 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,189.08 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $1,187.55 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $879.12 | 2019-2024 | Ztlido |
| Gilead Sciences, INC. | $729.13 | 2019-2025 | |
| Astellas Pharma US INC | $627.44 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $615.21 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $542.03 | 2021-2023 | |
| Pfizer INC. | $533.31 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $498.84 | 2023-2025 | Gemtesa |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.